Compare
Heartflow, Inc. vs SI-BONE, Inc. vs Neuronetics, Inc. vs Treace Medical Concepts, Inc.
| Latest fiscal year | Heartflow, Inc. HTFL | SI-BONE, Inc. SIBN | Neuronetics, Inc. STIM | Treace Medical Concepts, Inc. TMCI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $176.03M | $200.93M | $149.16M | $212.69M |
| Revenue growth (YoY) | +39.9% | +20.2% | +99.2% | +1.6% |
| Gross margin | 76.8% | 79.6% | 48.5% | 79.8% |
| Operating margin | -36.4% | -11.1% | -21.1% | -25.5% |
| Net margin | -66.3% | -9.4% | -26.1% | -27.7% |
| Net income | -$116.79M | -$18.90M | -$39.00M | -$59.00M |
| EPS (Diluted) | -$3.17 | -$0.44 | -$0.59 | -$0.93 |
| Operating cash flow | -$54.02M | -$675.0K | -$20.37M | -$15.97M |
| Free cash flow | -$59.05M | -$9.09M | -$21.18M | -$29.49M |
| Cash & equivalents | $44.78M | $42.24M | $28.13M | $10.71M |
| Total assets | $359.45M | $238.56M | $141.55M | $190.58M |
| Total liabilities | $58.80M | $61.02M | $115.31M | $103.25M |
| Shareholders' equity | $300.65M | $177.53M | $22.38M | $87.33M |
| Return on year-end equity | -38.8% | -10.6% | -174.3% | -67.6% |
| Shares outstanding | 85.28M | 43.65M | 68.99M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Heartflow, Inc. | SI-BONE, Inc. | Neuronetics, Inc. | Treace Medical Concepts, Inc. |
|---|---|---|---|---|
| Latest | $176.03M Ended 2025-12-31 | $200.93M Ended 2025-12-31 | $149.16M Ended 2025-12-31 | $212.69M Ended 2025-12-31 |
| 1 year earlier | $125.81M Ended 2024-12-31 | $167.18M Ended 2024-12-31 | $74.89M Ended 2024-12-31 | $209.36M Ended 2024-12-31 |
| 2 years earlier | $87.17M Ended 2023-12-31 | $138.89M Ended 2023-12-31 | $71.35M Ended 2023-12-31 | $187.12M Ended 2023-12-31 |
| 3 years earlier | n/a | $106.41M Ended 2022-12-31 | $65.21M Ended 2022-12-31 | $141.84M Ended 2022-12-31 |
| 4 years earlier | n/a | $90.15M Ended 2021-12-31 | $55.31M Ended 2021-12-31 | $94.42M Ended 2021-12-31 |